Targeting ROR1 in Chronic Lymphocytic Leukemia: Insights from the Zilovertamab and Ibrutinib Combination in High-Risk del(17p) Disease

Zilovertamab, a humanized monoclonal antibody against ROR1, was combined with the BTK inhibitor ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL), demonstrating a favorable safety profile without dose-limiting toxicities.
The combination effectively suppressed key pro-survival signaling cascades including NF-κB, ERK1/2, and mTORC1, confirming mechanistic inhibition of ROR1-mediated pathways.
A post hoc analysis suggested that patients with the high-risk del(17p) cytogenetic abnormality experienced prolonged disease control compared to historical BTK inhibitor monotherapy data, highlighting a potentially important therapeutic avenue.
The findings support further prospective evaluation of ROR1-targeted strategies combined with BTK inhibition in biologically high-risk CLL subgroups.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Zilovertamab, a humanized monoclonal antibody against ROR1, was combined with the BTK inhibitor ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL), demonstrating a favorable safety profile without dose-limiting toxicities.
The combination effectively suppressed key pro-survival signaling cascades including NF-κB, ERK1/2, and mTORC1, confirming mechanistic inhibition of ROR1-mediated pathways.
A post hoc analysis suggested that patients with the high-risk del(17p) cytogenetic abnormality experienced prolonged disease control compared to historical BTK inhibitor monotherapy data, highlighting a potentially important therapeutic avenue.
The findings support further prospective evaluation of ROR1-targeted strategies combined with BTK inhibition in biologically high-risk CLL subgroups.

Sign in free to continue reading